Latest Investor Relations News

Transurban's September quarter update reveals steady traffic growth across all key markets, underpinning a reaffirmed 6% increase in FY26 distributions.

Cyclopharm Ltd has been hit with legal proceedings by 4D Medical Limited, accusing it of making false and misleading statements during a March webinar. Cyclopharm denies the allegations, calling the claim without merit.

360 Capital Mortgage REIT has announced an unfranked ordinary dividend of AUD 0.055 per unit for the September quarter, alongside the adoption of the Attribution Managed Investment Trust (AMIT) tax regime.

Gryphon Capital Income Trust has announced a substantial non-underwritten Unit Purchase Plan, offering existing unitholders a chance to increase their stake at a slight discount. The offer aims to raise up to A$337 million to support its portfolio strategy.

One Click Group has locked in $1.25 million through a share placement, bringing Thorney Investment Group on board as a major shareholder and accelerating its Cash Advance product launch.

Magmatic Resources has responded to ASX queries over a recent spike in its share price and trading volume, confirming no undisclosed information exists. The company points to pending assay results from its Weebo Gold Project drilling as the likely catalyst for market interest.

Orion Minerals has increased its capital raising to A$8.6 million following additional commitments from sophisticated investors, signaling growing confidence in the company’s prospects.

Mont Royal Resources has lodged a Replacement Prospectus updating its financial disclosures and use of funds ahead of a pivotal shareholder meeting on 10 October to approve a merger with Commerce Resources.

Felix Gold Limited confirmed the materiality of a senior US federal officials' visit to its Treasure Creek Antimony Project, explaining the delayed disclosure was due to legal restrictions imposed by US authorities. The company affirmed compliance with ASX continuous disclosure rules following the announcement.

Equity Story Group Ltd has voluntarily suspended trading of its shares pending a forthcoming announcement about a capital raise, signaling a significant funding event.

Invex Therapeutics has ended negotiations on two neurological asset acquisitions following due diligence setbacks and shareholder disputes, while advancing R&D collaborations and managing financial stability.

Bank of Queensland announces a $170 million goodwill impairment in its retail banking unit for FY25, reflecting structural industry changes but maintaining strong cash earnings and capital ratios.